000			06224nam a22004575i 4500
999			_c120581 _d120581 _x1
001			120581
003			ES-MaUEC
005			20230102114049.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			200417s2020 gw a o |||| 0|eng d
020			_a9783030328573
024	7		_a10.1007/978-3-030-32857-3 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRM301.25 _b2020 EB
245	0	0	_aApproaching Complex Diseases : _bNetwork-Based Pharmacology and Systems Approach in Bio-Medicine _cedited by Mariano Bizzarri
250			_aFirst edition
264		1	_aCham, Switzerland _bSpringer International Publishing _c2020
300			_a1 recurso en línea (XVI, 483 páginas) _b49 ilustraciones, 41 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_aArchivo de texto _bPDF
490	0		_aHuman Perspectives in Health Sciences and Technology _x2661-8915 _v2
490	0		_aBiomedical and Life Sciences (Springer-11642)
505	0		_aChapter 1. Revisiting the concept of human disease (Mariano Bizzarri, Mirko Minini, and Noemi Monti) -- Chapter 2. Dynamical aspects of pharmacokinetic/pharmacodynamics and quantitative systems pharmacology models (Ioannis Loisios-Konstantinidis, Panteleimon D. Mavroudis, Panos Macheras) -- Chapter 3. The efficiency of multi-target drugs: a network approach (Lucas N. Alberca, Alan Talevi) -- Chapter 4. Mining Complex Biomedical Literature for Actionable Knowledge on Rare Diseases (Vinicius M. Alvesa, Stephen J. Capuzzia, Nancy Baker, Eugene N. Muratov, Alexander Trospsha, and Anthony J. Hickey) -- Chapter 5. Big Data, Personalized Medicine and Network Pharmacology: beyond the current paradigms (Alessandro Giuliani and Virginia Todde) -- Chapter 6. Epigenetic Control Using Small Molecules in Cancer (Tomohiro Kozako, Yukihiro Itoh, Shinichiro Honda, Takayoshi Suzuki) -- Chapter 7. Multiscale Modelling of Cancer: Micro-, Meso- and Macro-scales of Growth and Spread (Mark AJ Chaplain) -- Chapter 8. Precision Oncology vs Phenotypic approaches in the management of cancer: a case for the postmitotic state (Armando Aranda-Anzaldo and Myrna A.R. Dent) -- Chapter 9. Migrastatics - anti-metastatic drugs targeting cancer cell invasion (Aneta Gandalovičová , Daniel Rosel , Jan Brábek) -- Chapter 10. Critical steps in Epithelial-Mesenchymal transition as target for cancer treatment (Evgeny V. Denisov, Mohit Kumar Jolly, Vitaly P. Shubin, Alexey S. Tsukanov, Nadezhda V. Cherdyntseva) -- Chapter 11. Targeting the tumor-associated macrophages for 'normalizing' cancer (Julia Kzhyshkowska) -- Chapter 12. Tumor Reversion induced by embryo and oocyte extracts (Sara Proietti, Andrea Pensotti and Alessandra Cucina) -- Chapter 13. Trabectedin, a drug acting on both cancer cells and the tumor microenvironment (Paola Allavena, Manuela Liguori, Cristina Belgiovine) -- Chapter 14. Advances in Characterizing Recently-identified Molecular Actions of Melatonin: Clinical Implications (Russel J. Reiter, Ramaswamy Sharma, Sergio A. Rosales-Corral, Ana Coto-Montes, Jose Antonio Boga, Jerry Vriend) -- Chapter 15. Multitarget activities of Inositol and Inositol Hexakisphosphate (Ivana Vucenik) -- Chapter 16. Integration of Phytochemicals and Phytotherapy into Cancer Precision Medicine (Nadire Özenver and Thomas Efferth) -- Chapter 17. Synergistic Effects of Chinese Herbal Medicine and Biological Networks (Deep Jyoti Bhuyan, Saumya Perera1, Kirandeep Kaur, Muhammad A. Alsherbiny, Mitchell Low, Sai-Wang Seto, Chun-Guang Li, Xian Zhou) -- Chapter 18. Medicinal herbs: its therapeutic use in obstetrics and gynaecology (Irene Orbe, Daniel Paz, Leyre Pejenaute, Andrea Puente, Laura Diaz de Alda, Sandra Yague, Iñaki Lete) -- Chapter 19. Overcoming Antibiotic Resistance: New Perspectives (Matteo Bassetti, Elda Righi).
520	3		_aThis volume - for pharmacologists, systems biologists, philosophers and historians of medicine - points to investigate new avenues in pharmacology research, by providing a full assessment of the premises underlying a radical shift in the pharmacology paradigm. The pharmaceutical industry is currently facing unparalleled challenges in developing innovative drugs. While drug-developing scientists in the 1990s mostly welcomed the transformation into a target-based approach, two decades of experience shows that this model is failing to boost both drug discovery and efficiency. Selected targets were often not druggable and with poor disease linkage, leading to either high toxicity or poor efficacy. Therefore, a profound rethinking of the current paradigm is needed. Advances in systems biology are revealing a phenotypic robustness and a network structure that strongly suggest that exquisitely selective compounds, compared with multitarget drugs, may exhibit lower than desired clinical efficacy. This appreciation of the role of polypharmacology has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity. Integrating network biology and polypharmacology holds the promise of expanding the current opportunity space for druggable targets.
988			_aSpringer_Biomedlife_23062020
650		7	_aFarmacología _xInvestigación _2embne _9183058
650		7	_aIndustria farmacéutica _2embne _9138366
650		7	_aCiencias biomédicas _2embne _9143729
700	1		_aBizzarri, Mariano _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt _0http://id.loc.gov/authorities/names/no2003112202 _1http://viaf.org/viaf/193496217
710	2		_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _1http://viaf.org/viaf/148105729
776	0	8	_iPrinted edition: _z9783030328566
776	0	8	_iPrinted edition: _z9783030328580
776	0	8	_iPrinted edition: _z9783030328597
830		0	_aHuman Perspectives in Health Sciences and Technology, _x2661-8915 ; _v2
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-32857-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b07/2020 _dz _eo _zSI